Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.47
- Piotroski Score 3.00
- Grade Buy
- Symbol (MNMD)
- Company Mind Medicine (MindMed) Inc.
- Price $7.76
- Changes Percentage (-7.51%)
- Change -$0.63
- Day Low $7.73
- Day High $9.85
- Year High $12.22
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $20.00
- High Stock Price Target $22.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.93
- Trailing P/E Ratio -2.47
- Forward P/E Ratio -2.47
- P/E Growth -2.47
- Net Income $-95,732,000
Income Statement
Quarterly
Annual
Latest News of MNMD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading into 2025?
A list of top multibagger stocks includes Mind Medicine (MindMed) Inc. amidst market events like rate cuts and election outcomes. Fed Chair Powell suggests no urgency for more rate cuts due to solid e...
By Yahoo! Finance | 9 hours ago -
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions
Retail investors own the majority of shares in Mind Medicine (MindMed), influencing key decisions. Institutions and hedge funds also hold significant stakes, indicating credibility and potential growt...
By Yahoo! Finance | 2 days ago
